Caplin Steriles gets USFDA approval for Ketorolac Tromethamine Ophthalmic Solution

Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ketorolac tromethamine Ophthalmic Solution 0.5% (eye drops), a generic therapeutic equivalent version of (RLD), ACULAR Ophthalmic Solution of Allergan Inc.

Ketorolac tromethamine Ophthalmic Solution 0.5% is a nonsteroidal, anti- inflammatory indicated for the treatment of inflammation following cataract surgery and for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. According to IQVIATM (IMS Health), Ketorolac tromethamine Ophthalmic Solution 0.5% had US sales of approximately $36 million for the 12-month period ending December 2023.

Shares of Caplin Point Laboratories Limited was last trading in BSE at Rs. 1317.30 as compared to the previous close of Rs. 1259.95. The total number of shares traded during the day was 10903 in over 1200 trades.

The stock hit an intraday high of Rs. 1332.55 and intraday low of 1259.45. The net turnover during the day was Rs. 14132542.00.

Source : Equity Bulls

Keywords

CaplinPointLaboratories INE475E01026 CaplinSteriles USFDA FinalApproval ANDA KetorolacTromethamine OphthalmicSolution